Cystic fibrosis in Europe: improved lung function and longevity - reasons for cautious optimism, but challenges remain.

"Conflict of interest: L. Naehrlich reports grants from the German Center for Lung Research, Vertex Pharmaceuticals and Mukoviszidose Institute, participation on a trial steering committee for CF STORM, leadership roles as medical lead of the German CF Registry and pharmacovigilance study manager of the ECFSPR, and medical writing from Articulate Science, outside the submitted work. I. Sermet-Gaudelus reports grants, consulting fees and lecture honoraria from Vertex Pharmaceuticals, and a leadership role as medical lead of the French Pediatric CF Network, outside the submitted work. The remaining authors have no potential conflicts of interest to disclose."

"Conflict of interest: L. Naehrlich reports grants from the German Center for Lung Research, Vertex Pharmaceuticals and Mukoviszidose Institute, participation on a trial steering committee for CF STORM, leadership roles as medical lead of the German CF Registry and pharmacovigilance study manager of the ECFSPR, and medical writing from Articulate Science, outside the submitted work. I. Sermet-Gaudelus reports grants, consulting fees and lecture honoraria from Vertex Pharmaceuticals, and a leadership role as medical lead of the French Pediatric CF Network, outside the submitted work. The remaining authors have no potential conflicts of interest to disclose."